UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-39874 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) | Nevada | 20-2000871 | | --- | --- | ...

财务表现 - 公司净亏损从2023财年的6,712,525美元减少到2024财年的5,808,654美元，减少了903,871美元[199] - 2024财年总收入为464,278美元，比2023财年的226,208美元增加了238,070美元，增长率为105%[201] - 2024财年研发费用为2,360,565美元，比2023财年的3,666,721美元减少了1,306,156美元，减少了36%[204] - 2024财年一般和管理费用为3,852,021美元，比2023财年的3,062,009美元增加了790,012美元，增长率为26%[210] - 2024财年其他收入/损失减少122,979美元，降幅69%，从2023财年的亏损178,503美元降至亏损55,524美元[213] - 公司自进入生物科学领域以来，累计净亏损5160万美元，其中过去两个财年分别亏损580万美元和670万美元[214] - 公司预计在未来12个月及以后将继续产生重大运营费用和净亏损[214] - 2024财年，公司通过多种融资活动筹集了总计约1030万美元的净现金[226] - 截至2024年8月31日，公司现金及现金等价物为650万美元，足以满足未来12个月的预期研发和运营支出[220] - 2024财年，公司运营活动使用的净现金为495.9万美元，较2023财年的588.1万美元有所减少[222] - 2024财年，公司投资活动使用的净现金为18.86万美元，主要用于知识产权和设备的收购[225] - 2024财年，公司融资活动提供的净现金为1031.52万美元，主要来自股票销售和认股权证的行使[226] - 2024财年，公司营运资本增加了约490万美元，主要由于融资活动产生的现金和运营活动使用的现金的净影响[221] 研发进展 - 公司继续推进DehydraTECH技术在GLP-1和GIP药物中的应用，完成了两项人体试验和一项动物试验[193] - 公司已开始筹备为期12周的慢性糖尿病患者临床试验，比较DehydraTECH-CBD、DehydraTECH-semaglutide等药物与Rybelsus®对照组的效果[188] - 公司在2024财年获得了10项新专利，包括首次用于治疗癫痫的专利[191] - 公司计划在2025财年推进高血压相关研究的IND申请，预计在2025年第一季度提交相关文件[206] 战略与合作 - 公司预计现有现金储备将满足未来12个月的运营需求[198] - 公司正在探索战略性企业合作，以生成足够的数据支持未来的里程碑和/或特许权使用费支付[198] - 公司现有现金不足以完成FDA批准产品候选的全面开发、测试和商业化，需要进一步融资或达成行业合作伙伴关系[215]

For the quarterly period ended May 31, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) V1X2P7 (ZipCode) Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a shel ...

For the transition period from [ ] to [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Commission file number 000-52138 Nevada 20-2000871 LEXARIA BIOSCIENCE CORP. (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) | Nevada | 20-2000871 | | --- | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [____] to [____] Commission file number 000-52138 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) State or other jurisdiction of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 20-2000871 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 20-2000871 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 20-2000871 State or other jurisdiction o ...